nature.com search

Loading Filters

Showing 1–31 of 31 results

Loading Filters

Amendments and Corrections | 13 February 2008
Erratum: Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature
- W J Chng
- , W M Kuehl
- , P L Bergsagel
- & R Fonseca
Leukemia 22 , 462–462

Rights & permissionsfor article Erratum: Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature . Opens in a new window.
20 March 2015 | Open
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation
- V Roy
- , A K Stewart
- , P L Bergsagel
- , A Dispenzieri
- , K Laumann
- , J Allred
- , M Q Lacy
- , R Fonseca
- , C B Reeder
- , S Kumar
- , C E Rivera
- , M A Gertz
- , F K Buadi
- , S R Hayman
- & S V Rajkumar
Blood Cancer Journal 5 , e294–e294

Rights & permissionsfor article Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation . Opens in a new window.
6 May 2013
Degree of focal immunoglobulin heavy chain locus deletion as a measure of B-cell tumor purity
- P L Bergsagel
- & W M Kuehl
Leukemia 27 , 2067–2068

Rights & permissionsfor article Degree of focal immunoglobulin heavy chain locus deletion as a measure of B-cell tumor purity . Opens in a new window.
8 March 2007
Expression and mutation status of candidate kinases in multiple myeloma
- J O Claudio
- , F Zhan
- , L Zhuang
- , R Khaja
- , Y X Zhu
- , K Sivananthan
- , S Trudel
- , E Masih-Khan
- , R Fonseca
- , P L Bergsagel
- , S W Scherer
- , J Shaughnessy
- & A K Stewart
Leukemia 21 , 1124–1127

Rights & permissionsfor article Expression and mutation status of candidate kinases in multiple myeloma . Opens in a new window.
6 September 2007
Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature
- W J Chng
- , W M Kuehl
- , P L Bergsagel
- & R Fonseca
Leukemia 22 , 459–461

Rights & permissionsfor article Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature . Opens in a new window.
7 August 2008
Reply to the research mission in myeloma by Richardson et al.
- P L Bergsagel
Leukemia 23 , 423–424

Rights & permissionsfor article Reply to the research mission in myeloma by Richardson et al. . Opens in a new window.
Amendments and Corrections | 16 April 2008
Erratum: Expression and mutation status of candidate kinases in multiple myeloma
- J O Claudio
- , F Zhan
- , L Zhuang
- , R Khaja
- , Y X Zhu
- , K Sivananthan
- , S Trudel
- , E Masih-Khan
- , R Fonseca
- , P L Bergsagel
- , S W Scherer
- , J Shaughnessy
- & A K Stewart
Leukemia 22 , 889–890

Rights & permissionsfor article Erratum: Expression and mutation status of candidate kinases in multiple myeloma . Opens in a new window.
Correspondence | 21 April 2005
Maintained rules of development in a mouse B-cell tumor
- D F Robbiani
- , K Colon
- , M Affer
- , M Chesi
- & P L Bergsagel
Leukemia 19 , 1278–1280

Rights & permissionsfor article Maintained rules of development in a mouse B-cell tumor . Opens in a new window.
24 January 2008
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma
- H Paripati
- , A K Stewart
- , S Cabou
- , A Dueck
- , V J Zepeda
- , N Pirooz
- , C Ehlenbeck
- , C Reeder
- , J Slack
- , J F Leis
- , J Boesiger
- , A S Torloni
- , R Fonseca
- & P L Bergsagel
Leukemia 22 , 1282–1284

Rights & permissionsfor article Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma . Opens in a new window.
14 June 2007
Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution
- A K Stewart
- , H Chang
- , S Trudel
- , K C Anderson
- , P Richardson
- , M Alsina
- , D Reece
- , S Young
- , A Sable-Hunt
- , Z Li
- , J Keats
- , S Van Wier
- , G Ahmann
- , T Price-Troska
- , K Giusti
- , P L Bergsagel
- , M Chesi
- & R Fonseca
Leukemia 21 , 2358–2359

Rights & permissionsfor article Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution . Opens in a new window.
Editorial | 16 April 2008
A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy
- P L Bergsagel
Leukemia 22 , 673–675

Rights & permissionsfor article A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy . Opens in a new window.
Research | 1 September 2017
Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial
- S Ailawadhi
- , J R Mikhael
- , B R LaPlant
- , K M Laumann
- , S Kumar
- , V Roy
- , D Dingli
- , P L Bergsagel
- , F K Buadi
- , S V Rajkumar
- , R Fonseca
- , M A Gertz
- , P Kapoor
- , T Sher
- , S R Hayman
- , A K Stewart
- , A Dispenzieri
- , R A Kyle
- , W I Gonsalves
- , C B Reeder
- , Y Lin
- , R S Go
- , N Leung
- , T Kourelis
- , J A Lust
- , S J Russell
- , A A Chanan-Khan
- & M Q Lacy
Leukemia 32 , 719–728

Rights & permissionsfor article Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial . Opens in a new window.
Research | 16 June 2017 | Open
Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma
- P Ravi
- , S Kumar
- , W Gonsalves
- , F Buadi
- , M Q Lacy
- , R S Go
- , A Dispenzieri
- , P Kapoor
- , J A Lust
- , D Dingli
- , Y Lin
- , S J Russell
- , N Leung
- , M A Gertz
- , R A Kyle
- , P L Bergsagel
- & S V Rajkumar
Blood Cancer Journal 7 , e569–e569

Rights & permissionsfor article Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma . Opens in a new window.
Research | 29 July 2016 | Open
Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma
- P Ravi
- , S Kumar
- , J T Larsen
- , W Gonsalves
- , F Buadi
- , M Q Lacy
- , R Go
- , A Dispenzieri
- , P Kapoor
- , J A Lust
- , D Dingli
- , Y Lin
- , S J Russell
- , N Leung
- , M A Gertz
- , R A Kyle
- , P L Bergsagel
- & S V Rajkumar
Blood Cancer Journal 6 , e454–e454

Rights & permissionsfor article Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma . Opens in a new window.
Research | 26 February 2016 | Open
Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients
- K M Kortuem
- , E Braggio
- , L Bruins
- , S Barrio
- , C S Shi
- , Y X Zhu
- , R Tibes
- , D Viswanatha
- , P Votruba
- , G Ahmann
- , R Fonseca
- , P Jedlowski
- , I Schlam
- , S Kumar
- , P L Bergsagel
- & A K Stewart
Blood Cancer Journal 6 , e397–e397

Rights & permissionsfor article Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients . Opens in a new window.
24 November 2016
Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma
- J Bordini
- , S Galvan
- , M Ponzoni
- , M T S Bertilaccio
- , M Chesi
- , P L Bergsagel
- , C Camaschella
- & A Campanella
Leukemia 31 , 967–970

Rights & permissionsfor article Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma . Opens in a new window.
Research | 15 January 2016 | Open
Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
- A Rosenthal
- , J Luthi
- , M Belohlavek
- , K M Kortüm
- , F Mookadam
- , A Mayo
- , R Fonseca
- , P L Bergsagel
- , C B Reeder
- , J R Mikhael
- & A K Stewart
Blood Cancer Journal 6 , e384–e384

Rights & permissionsfor article Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? . Opens in a new window.
Research | 14 August 2015 | Open
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
- S K Kumar
- , B LaPlant
- , V Roy
- , C B Reeder
- , M Q Lacy
- , M A Gertz
- , K Laumann
- , M A Thompson
- , T E Witzig
- , F K Buadi
- , C E Rivera
- , J R Mikhael
- , P L Bergsagel
- , P Kapoor
- , L Hwa
- , R Fonseca
- , A K Stewart
- , A Chanan-Khan
- , S V Rajkumar
- & A Dispenzieri
Blood Cancer Journal 5 , e338–e338

Rights & permissionsfor article Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib . Opens in a new window.
Research | 9 September 2010
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
- M Q Lacy
- , S R Hayman
- , M A Gertz
- , K D Short
- , A Dispenzieri
- , S Kumar
- , P R Greipp
- , J A Lust
- , S J Russell
- , D Dingli
- , S Zeldenrust
- , R Fonseca
- , P L Bergsagel
- , V Roy
- , J R Mikhael
- , A K Stewart
- , K Laumann
- , J B Allred
- , S J Mandrekar
- , S V Rajkumar
- & F Buadi
Leukemia 24 , 1934–1939

Rights & permissionsfor article Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) . Opens in a new window.
Research | 19 February 2009
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
- C B Reeder
- , D E Reece
- , V Kukreti
- , C Chen
- , S Trudel
- , J Hentz
- , B Noble
- , N A Pirooz
- , J E Spong
- , J G Piza
- , V H J Zepeda
- , J R Mikhael
- , J F Leis
- , P L Bergsagel
- , R Fonseca
- & A K Stewart
Leukemia 23 , 1337–1341

Rights & permissionsfor article Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial . Opens in a new window.
Research | 18 January 2007
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
- A K Stewart
- , P L Bergsagel
- , P R Greipp
- , A Dispenzieri
- , M A Gertz
- , S R Hayman
- , S Kumar
- , M Q Lacy
- , J A Lust
- , S J Russell
- , T E Witzig
- , S R Zeldenrust
- , D Dingli
- , C B Reeder
- , V Roy
- , R A Kyle
- , S V Rajkumar
- & R Fonseca
Leukemia 21 , 529–534

Rights & permissionsfor article A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy . Opens in a new window.
Research | 2 March 2006
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations
- W J Chng
- , R Santana-Dávila
- , S A Van Wier
- , G J Ahmann
- , S M Jalal
- , P L Bergsagel
- , M Chesi
- , M C Trendle
- , S Jacobus
- , E Blood
- , M M Oken
- , K Henderson
- , R A Kyle
- , M A Gertz
- , M Q Lacy
- , A Dispenzieri
- , P R Greipp
- & R Fonseca
Leukemia 20 , 807–813

Rights & permissionsfor article Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations . Opens in a new window.
Research | 11 March 2010
Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma
- W J Chng
- , M A Gertz
- , T-H Chung
- , S Van Wier
- , J J Keats
- , A Baker
- , P L Bergsagel
- , J Carpten
- & R Fonseca
Leukemia 24 , 833–842

Rights & permissionsfor article Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma . Opens in a new window.
Research | 5 October 2006
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma
- R Fonseca
- , S A Van Wier
- , W J Chng
- , R Ketterling
- , M Q Lacy
- , A Dispenzieri
- , P L Bergsagel
- , S V Rajkumar
- , P R Greipp
- , M R Litzow
- , T Price-Troska
- , K J Henderson
- , G J Ahmann
- & M A Gertz
Leukemia 20 , 2034–2040

Rights & permissionsfor article Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma . Opens in a new window.
Research | 31 March 2017 | Open
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
- C Pawlyn
- , M D Bright
- , A F Buros
- , C K Stein
- , Z Walters
- , L I Aronson
- , F Mirabella
- , J R Jones
- , M F Kaiser
- , B A Walker
- , G H Jackson
- , P A Clarke
- , P L Bergsagel
- , P Workman
- , M Chesi
- , G J Morgan
- & F E Davies
Blood Cancer Journal 7 , e549–e549

Rights & permissionsfor article Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control . Opens in a new window.
Research | 12 September 2013 | Open
Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma
- G M Matthews
- , M Lefebure
- , M A Doyle
- , J Shortt
- , J Ellul
- , M Chesi
- , K-M Banks
- , E Vidacs
- , D Faulkner
- , P Atadja
- , P L Bergsagel
- & R W Johnstone
Cell Death & Disease 4 , e798–e798

Rights & permissionsfor article Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma . Opens in a new window.
Research | 12 February 2014
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma
- M Affer
- , M Chesi
- , W D Chen
- , J J Keats
- , Y N Demchenko
- , K Tamizhmani
- , V M Garbitt
- , D L Riggs
- , L A Brents
- , A V Roschke
- , S Van Wier
- , R Fonseca
- , P L Bergsagel
- & W M Kuehl
Leukemia 28 , 1725–1735

Rights & permissionsfor article Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma . Opens in a new window.
Research | 11 June 2013
Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276
- J Schmidt
- , E Braggio
- , K M Kortuem
- , J B Egan
- , Y X Zhu
- , C S Xin
- , R E Tiedemann
- , S E Palmer
- , V M Garbitt
- , D McCauley
- , M Kauffman
- , S Shacham
- , M Chesi
- , P L Bergsagel
- & A K Stewart
Leukemia 27 , 2357–2365

Rights & permissionsfor article Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276 . Opens in a new window.
Research | 5 April 2011
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
- W-J Chng
- , G F Huang
- , T H Chung
- , S B Ng
- , N Gonzalez-Paz
- , T Troska-Price
- , G Mulligan
- , M Chesi
- , P L Bergsagel
- & R Fonseca
Leukemia 25 , 1026–1035

Rights & permissionsfor article Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma . Opens in a new window.
1 October 2009
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
- R Fonseca
- , P L Bergsagel
- , J Drach
- , J Shaughnessy
- , N Gutierrez
- , A K Stewart
- , G Morgan
- , B Van Ness
- , M Chesi
- , S Minvielle
- , A Neri
- , B Barlogie
- , W M Kuehl
- , P Liebisch
- , F Davies
- , S Chen-Kiang
- , B G M Durie
- , R Carrasco
- , Orhan Sezer
- , Tony Reiman
- , Linda Pilarski
- & H Avet-Loiseau
Leukemia 23 , 2210–2221

Rights & permissionsfor article International Myeloma Working Group molecular classification of multiple myeloma: spotlight review . Opens in a new window.
Research | 24 January 2008
Genetic aberrations and survival in plasma cell leukemia
- R E Tiedemann
- , N Gonzalez-Paz
- , R A Kyle
- , R Santana-Davila
- , T Price-Troska
- , S A Van Wier
- , W J Chng
- , R P Ketterling
- , M A Gertz
- , K Henderson
- , P R Greipp
- , A Dispenzieri
- , M Q Lacy
- , S V Rajkumar
- , P L Bergsagel
- , A K Stewart
- & R Fonseca
Leukemia 22 , 1044–1052

Rights & permissionsfor article Genetic aberrations and survival in plasma cell leukemia . Opens in a new window.

Refine your results by…

Filters

Filter By:

Erratum: Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature

Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation

Degree of focal immunoglobulin heavy chain locus deletion as a measure of B-cell tumor purity

Expression and mutation status of candidate kinases in multiple myeloma

Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature

Reply to the research mission in myeloma by Richardson et al.

Erratum: Expression and mutation status of candidate kinases in multiple myeloma

Maintained rules of development in a mouse B-cell tumor

Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma

Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution

A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy

Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma

Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients

Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations

Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma

Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma

Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

Genetic aberrations and survival in plasma cell leukemia

Quick links

Refine your results by…

Filters ​

Filter By:

Search

Quick links

Filters